New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 10, 2019 - Xeris Pharmaceuticals announced the FDA approval of Gvoke (glucagon), for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above.
Download PDF
Return to publications